logo
Share SHARE
FONT-SIZE Plus   Neg

Cytokinetics Reports Results From Phase II Clinical Trials Evaluating CK-2017357

Cytokinetics, Inc. (CYTK) announced encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease.

Jeremy Shefner, Professor and Chair of the Department of Neurology at the Upstate Medical University at the State University of New York, concluded that CK-2017357 appeared to be safe and well-tolerated dosed daily at 125 mg, 250 mg, and 375 for two weeks, and that encouraging trends were observed in the ALSFRS-R and MVV. As expected, plasma concentrations of CK-2017357 were unaffected by co-administration with riluzole, while riluzole levels increased during co-administration with CK-2017357.

Adverse events and clinical assessments during treatment with CK-2017357 appeared similar, with or without co-administration of riluzole at the reduced dose of 50 mg daily. Dizziness, the most commonly reported adverse event, was mostly mild and generally began and resolved early after initiating treatment.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
LinkedIn Corp. (LNKD) on Thursday posted a loss for the first-quarter that widened from a year ago, hurt largely by higher operating costs. On an adjusted basis, earnings for the quarter improved and trumped Wall Street estimates, as revenues jumped 35 percent led by growth across all segments. Shares... Daily deals site Groupon Inc. (GRPN) on Thursday reported a loss for the first quarter that widened from a year ago, hurt largely by lower revenues. Nevertheless, loss for the quarter were lower than what Wall Street expected, revenues also trumped estimates. Chicago, Illinois-based Groupon's first-quarter... Shares of Amazon.com Inc. (AMZN) jumped 12 percent in after-hours on Thursday after the online retailer reported a first-quarter profit and revenues that trumped Wall Street estimates. Seattle, Washington-based Amazon reported first-quarter profit of $513 million or $1.07 per share, compared with...
comments powered by Disqus
Follow RTT